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(for HEC: aprepitant days1–3, ondansetron 32mg IV day1; for
MEC: aprepitant days1–3, ondansetron 16mg PO day1), versus
a standard regimen (for HEC: ondansetron 32mg IV day1 and
16mg PO days2–4; for MEC: ondansetron 16mg PO days1–3).
The second analysis is based on current real-world resource use
in the prevention of CINV using the IMS Longitudinal Hospital
Database (with ondansetron PO only used in 53% (MEC) to
58% (HEC) of patients but at 132% (MEC) and 66% (HEC)
higher doses). CINV-speciﬁc utility values adapted from Sun et
al. (2002) were used to calculate QALYs. Drug costs were
obtained from ofﬁcial listings. Treatment costs for CINV were
obtained from a German study and adapted to Belgium.
RESULTS: The aprepitant-based regimen is associated with
0.003 and 0.014 more QALY’s in HEC and MEC respectively
and with savings of 66.84€ (trial based) and 74.62€ (real life
based) for HEC and 17.95€ (trial based) and 21.70€ (real life
based) for MEC. Hence, aprepitant is both more effective and
less expensive (= dominant). Sensitivity analyses were performed
on treatment cost of emesis and on the clinical beneﬁt of aprepi-
tant and showed that the results were very robust. CONCLU-
SIONS: In both approaches the aprepitant-based strategy is
dominant.
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OBJECTIVES: To evaluate cost effectiveness (CE) of Paclitaxel
compared to Docetaxel for Anthracycline pretreated metastatic
breast cancer (MBC) patients from a societal perspective.
METHODS: A two year decision model was developed with
parameter inputs from published literature and the ﬁrst phase III
randomized clinical trial which compared the taxanes for treat-
ment of MBC. Direct cost (in 2005 $) included in the model were
drug and premedication cost, administration and personnel cost,
cost of hospitalization and adverse effects, laboratory cost, home
health aide cost along with follow up and terminal care cost.
Indirect cost consisted of informal caregiver time and patient
time cost. Effectiveness was measured in terms of quality
adjusted life years (QALYs), which was based on utilities elicited
from US oncology nurses and life expectancy calculated using
declining exponential approximation of life expectancy (DEALE)
method. All costs and QALYs were discounted at 3% and an
incremental cost effectiveness ratio (ICER) was calculated.
Uncertainty of point estimates was analyzed in Univariate sensi-
tivity analysis. Threshold sensitivity analysis was also conducted
to evaluate the values where the CE ratio changed. RESULTS:
Paclitaxel was more cost effective for treatment of MBC,
amongst the two taxanes. Docetaxel drug cost and adversity
proﬁle made the ICER $145,837/QALY gained. The model 
was robust to reasonable changes to the parameter estimates.
Response to treatment was one of the key parameters which
affected the CE ratio. Threshold analysis suggested, either Doc-
etaxel response rate should increase to 42% or Paclitaxel
response rate decrease by a third or the price of Docetaxel
decrease by one sixth, to bring the ICER close to the
$100,000/QALY. CONCLUSIONS: Docetaxel may be a better
choice from clinical stand point for treatment of MBC patients,
but its economic justiﬁcation is questionable in a cost conscious
society with limited resources.
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OBJECTIVES: The purpose of the study is to calculate the
annual health insurance cost of treatment of colorectal cancer at
nationwide level in Hungary for the year 2001. METHODS:
Data derive from the nationwide database of the Hungarian
National Health Insurance Fund Administration (OEP), the only
health care ﬁnancing agency in Hungary. The cost of treatment
includes: out-patient care, acute and chronic inpatient care, sub-
sidies of medicines’ prices (ATC groups: “L”, antineoplastic and
immunomodulating agents, “N02”, Analgesics and “A04”
Antiemetics and antineuseants) and expenditure on disability to
work (including sickness-pay). According to standard cost cate-
gories direct medical and direct non-medical costs, indirect (pro-
ductivity) costs are included while informal care and intangible
costs are excluded. Disease was identiﬁed with the following
ICD-10 codes: C18, C19, C20, C21 (Malignant neoplasm of
colon, rectosigmoid junction, rectum and anus and anal canal),
D01.0, D01.1, D01.2, D01.3, D01.4 (carcinoma in situ), D12
(Benign neoplasm of colon, rectum, anus and anal canal).
RESULTS: The results showed the following cost structure. Out-
patient care: $1,889,315 or €2,109,102 (5.4% of total costs),
acute inpatient care: $25,994,160 or €29,018,103 (74.7% of
total costs), chronic inpatient care: $1,293,650 or €1,444,142
(3.7% of total costs), sickness-pay: $1,293,057 or €1,443,480
(3.7% of total costs), drugs from outpatient care’s budget:
$4,350,714 or €4,856,839 (12.5% of total costs). The National
Health Insurance Fund Administration (OEP) spent alltogether
$34,820,895 or €38,871,666 on colorectal cancer in 2001. Most
of the costs (82.8%) derived from malignant neoplasms, 17.0%
from benign neoplasms including polyps and 0.2% from in situ
cancers. CONCLUSIONS: Colorectal cancer represents a large
burden in Hungary. Benign neoplasms including polyps repre-
sents an important cost element. Most of the costs come from
acute in-patient care.
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OBJECTIVES: Published data on costs associated with treating
Medicare patients with hepatocellular carcinoma (HCC) or
metastatic liver disease (MLD) are limited. This study evaluated
health resource use and medical costs in patients newly diag-
nosed with HCC or MLD. METHODS: Patients ≥ 65 years of
age with an HCC or MLD diagnosis were identiﬁed in the 2002
Medicare 5% sample Standard Analytic File and followed for 1
year after the ﬁrst diagnosis. Patients with HMO enrollment or
a prior HCC or MLD diagnosis were excluded. Total health
resource use and medical costs, including hospital inpatient, out-
patient, and physician and supplier services, were measured from
the Medicare payment perspective. RESULTS: The study
included 281 HCC and 1371 MLD patients (mean age 74.8
years; 45% male). Over 1 year, MLD patients had signiﬁcantly
higher outpatient services than HCC patients (10.3 vs. 13.3, p <
0.001), as well as signiﬁcantly more physician encounters,
including ofﬁce visits (p < 0.001). There was no difference in hos-
